← All trials
NCT01237483
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2010
- Primary completion
- Dec 1, 2014
- Completion date
- Feb 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 62
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Groupe Oncologie Radiotherapie Tete et CouLead sponsor
- University of Picardie Jules VerneOverall official - principal investigator
- Polyclinique du Parc, 31078 Toulouse, FranceOverall official - principal investigator
- Institut Gustave RoussyOverall official - principal investigator
- University of LyonOverall official - principal investigator
- Centre Hospitalier de Saint-BrieucOverall official - principal investigator
- Clinique de l' Estuaire, PornichetOverall official - principal investigator
- University of LimogesOverall official - principal investigator
- Clinique PasteurOverall official - principal investigator
- Val d'Aurelle Cancer InstituteOverall official - principal investigator
- University of PoitiersOverall official - principal investigator
- Centre Georges Francois LeclercOverall official - principal investigator
- Centre Henri BecquerelOverall official - principal investigator
- Centre Jean BernardOverall official - principal investigator
- Centre Jean PerrinOverall official - principal investigator
- Centre Paul StraussOverall official - principal investigator
- Institut Sainte CatherineOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
- University of AngersOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.